• Apigenin: Protocol Innovations for Cancer and Neuroprotectio

  2026-06-17

  Apigenin (5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one) bridges oncology and neurodegeneration workflows with robust HDAC inhibition and multi-pathway modulation. Learn how APExBIO’s Apigenin enables streamlined setups, data-driven optimizations, and reliable troubleshooting for advanced cancer and Alzheimer’s disease models.

• NU7441 (KU-57788): Bridging DNA Repair Mechanisms to Oncolog

  2026-06-17

  This thought-leadership article explores how the selective DNA-PK inhibitor NU7441 (KU-57788) is advancing both DNA repair and oncology research. It spotlights mechanistic insights into DNA damage response, summarizes experimental findings, positions NU7441 within the translational research landscape, and provides strategic guidance for investigators in neuroinflammation and cancer. The article leverages recent studies on HIV-1-induced DNA repair vulnerability, contextualizes APExBIO's NU7441 as a uniquely potent tool, and outlines the next frontiers for precision medicine.

• LINC01550 Suppresses Colorectal Cancer via Wnt/β-Catenin Inh

  2026-06-16

  This study reveals that the long noncoding RNA LINC01550 is downregulated in colorectal cancer and acts as a tumor suppressor by inhibiting the Wnt/β-catenin pathway. The findings highlight LINC01550's potential as both a prognostic biomarker and a therapeutic target in colorectal cancer.

• Mavorixafor Hydrochloride: Redefining CXCR4 Antagonist Use i

  2026-06-16

  Explore how Mavorixafor hydrochloride (AMD-070 hydrochloride), a potent CXCR4 antagonist, is unlocking new frontiers in ischemia research and anti-HIV strategies. This article uniquely bridges CXCR4 signaling with tissue perfusion insights, providing advanced protocol guidance and practical assay considerations for biomedical scientists.

• GSH-Responsive MOF Nanoparticles Enhance Melanoma Therapy

  2026-06-15

  Hao et al. designed glutathione-responsive metal-organic framework (MOF) nanoparticles, loaded with indocyanine green (ICG) and modified with a PD-1 inhibitory peptide, for synergistic photothermal and immunotherapy in melanoma. This approach demonstrated targeted immune checkpoint blockade and potent tumor ablation, highlighting a promising direction for next-generation cancer nanomedicines.

• SHC-1 Inhibition Uncovers CFTR Trafficking Mechanisms in Epi

  2026-06-15

  Barros et al. systematically dissect how SHC-1 inhibition modulates the plasma membrane abundance of the CFTR chloride channel across distinct epithelial cell models. Their work clarifies conserved and context-dependent mechanisms of CFTR trafficking, informing both cystic fibrosis research and the design of secretory diarrhea assays.

• BnaMAPK1 Enhances Shading Tolerance in Rapeseed via Photosys

  2026-06-14

  This study uncovers how the mitogen-activated protein kinase BnaMAPK1 enhances shading tolerance in rapeseed by regulating photosystem II, specifically through interactions with light-harvesting complexes. These findings inform strategies for breeding stress-resilient Brassica napus and provide mechanistic insight into plant responses to low-light environments.

• Ceramide Metabolism Drives RGNNV Replication via Autophagy M

  2026-06-13

  This study elucidates how red-spotted grouper nervous necrosis virus (RGNNV) manipulates ceramide metabolism to facilitate viral replication in fish cells. By integrating global lipidomics and targeted functional assays, the authors identify ceramides—especially C16-ceramide—as key pro-viral mediators that promote autophagy, offering new mechanistic insights for antiviral strategy development.

• PP 1 (Src Family Tyrosine Kinase Inhibitor): Precision Contr

  2026-06-12

  Explore how PP 1, a potent Src family tyrosine kinase inhibitor, enables unprecedented precision in dissecting immune and oncogenic signaling pathways. This article uniquely bridges advanced mechanistic insight with next-generation assay design, offering researchers actionable guidance grounded in recent machine learning breakthroughs.

• Practical Use of DiI (DiIC18(3)) Plasma Membrane Probe

  2026-06-12

  DiI (DiIC18(3)) enables selective, high-contrast plasma membrane labeling in live and fixed cells, providing robust orange-red fluorescence for applications such as neuronal tracing, cell migration assays, and membrane-specific analyses. It should not be used for aqueous protocols or exclusive intracellular organelle labeling, and strict attention to solvent compatibility and membrane integrity is required for optimal results.

• 3-Bromopyruvate and Cetuximab Co-Treatment Reverses CRC Resi

  2026-06-11

  This study demonstrates that combining 3-bromopyruvate with cetuximab effectively overcomes cetuximab resistance in colorectal cancer by inducing autophagy-dependent ferroptosis and apoptosis. The elucidation of FOXO3a pathway modulation offers new translational avenues for targeting drug-resistant CRC.

• ECL Chemiluminescent Substrate Kit: Hypersensitive Detection

  2026-06-11

  The ECL Chemiluminescent Substrate Detection Kit (Hypersensitive) enables ultrasensitive, HRP-based chemiluminescent detection of proteins on nitrocellulose or PVDF membranes. This kit supports low picogram-level sensitivity, long signal duration, and minimal background, making it highly effective for immunoblotting detection of low-abundance proteins.

• TG003: Cdc2-like Kinase Inhibitor for Alternative Splicing R

  2026-06-10

  TG003 is a nanomolar-potency Cdc2-like kinase inhibitor that enables precise modulation of alternative splicing and splice site selection. It is widely used in research on platinum resistance mechanisms and exon-skipping therapies. Benchmark studies highlight its specificity, reproducibility, and utility in both cellular and animal models.

• Structural Insights into TRPM3 Modulation by Neurosteroids a

  2026-06-10

  This study reveals high-resolution cryo-EM structures of the TRPM3 ion channel in complex with neurosteroids and the anticonvulsant primidone, providing a molecular basis for TRPM3 regulation. The findings clarify how disease mutations and pharmacological agents modulate channel gating, offering pathways for developing targeted therapies for pain and neurodevelopmental disorders.

• 25-Hydroxycholesterol Drives Immunosuppressive Macrophage Re

  2026-06-09

  Xiao et al. (2024) uncover how 25-hydroxycholesterol (25HC), produced by CH25H, accumulates in lysosomes of tumor-associated macrophages, activating AMPK and reprogramming metabolism to promote immunosuppression. These findings establish CH25H as a metabolic checkpoint and suggest new strategies for modulating tumor immunity.

16411 records 1/1095 page Next 12345 下5页 Last page